Acquisition Announced
XRA 7 Corp. acquisition of Generation Bio Co.
Announced 15 Dec 2025 · US$4.29 cash and scrip per share
Advisers
Generation Bio Co.
Target
- Financial adviser
- TD Securities (as TD Cowen)
- Legal adviser
- Fairness opinion
- TD Securities (as TD Cowen)
- Target
- Generation Bio Co.
- Acquirer
- XRA 7 Corp.
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Life Sciences
In the league tables
Similar deals
- BRUKER acquisition of MIMETAS Aug 2026 · Life Sciences
- Oberland Capital Management stake in MeiraGTx Holdings Jul 2026 · Biotech
- Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Jun 2026 · Biotech
- Ligand Pharmaceuticals acquisition of XOMA Royalty Apr 2026 · US$739m · Specialty finance and leasing
- Invex Therapeutics acquisition of Rekover Therapeutics Oct 2026 · Healthcare
Sources
- 9 Jan 2026 Target response to tender offer (SC 14D9), Generation Bio Co. sec.gov
- 9 Jan 2026 Tender offer statement (SC TO-T), Generation Bio Co. sec.gov
